Business Monitor International


United Arab Emirates Pharmaceuticals & Healthcare Report

Published 25 March 2014

  • 122 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
United Arab Emirates Pharmaceuticals & Healthcare Report

BMI View: The UAE is one of the more developed markets in the Middle East and has a strong existing healthcare infrastructure. As the UAE is aiming to introduce comprehensive health insurance throughout the country , allowing businesses to shoulder much of the cost of this expanded coverage, the government will gradually contribute less to the country's healthcare spending. Between 2013 and 2018, we expect private sector healthcare spending to outpace public. However, the public sector will remain the main source of healthcare expenditure, contributing over 60% of total spending by 2023.

Headline Expenditure Projections:

  • Pharmaceuticals: AED7.02bn (USD1.91bn) in 2013 to AED7.44bn (USD2.03bn) in 2014; +6.0% in local currency and +6.1% in US dollar terms. Forecast in line with previous quarter.

  • Healthcare: AED42.60bn (USD11.60bn) in 2013 to AED45.82bn (USD12.48bn) in 2014; +7.6% in local currency terms and US dollar terms. Forecast revised down from previous quarter due to recently released WHO data.

Risk/Reward Rating

The UAE has moved up one place in our Pharmaceutical Risk/Reward Rating (RRR). In Q3 2014 it ranks third out of a total of 30 markets in the Middle East and Africa region, with a score of 57.4.

Key Trends & Developments

June

The UAE is among the first five countries in the Arab world to implement an updated and more stringent set of healthcare measures, which will be effective from July 1 2015, reports Gulf Today. The new measures will guarantee public health safety and benefits, in the midst of an increasing number of drugs and treatment methods flooding the market. The main aim is to ensure that all pharmaceutical products entering the region are safe and effective, so that the increasing incidence of disease is mitigated. May

The UAE's health ministry announced that rotavirus vaccination is mandatory for all babies in the country, reports the National. The vaccine, which protects against the deadly virus that causes gastroenteritis,...

Table of Contents

BMI Industry View
7
SWOT
9
Business Environment
11
Economic
12
Political
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales Indicators 2009-2017
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Indicators 2009-2017
18
Table: Healthcare Governmental Indicators 2009-2017
18
Table: Healthcare Private Indicators 2009-2017
19
Prescription Market Forecast
19
Table: UAE Healthcare Demand Split By Therapeutic Area
20
Table: Prescription Drug Sales Indicators 2009-2017
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, 2009-2017
23
Generic Drug Market Forecast
23
Table: Generic Drug Sales Indicators, 2009-2017
24
OTC Medicine Market Forecast
25
Table: OTC Medicine Sales Indicators, 2009-2017
26
Pharmaceutical Trade Forecast
27
Table: Exports And Imports Indicators, 2009-2017
28
Other Healthcare Data
28
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Dubai: Confident As Ever
31
Oman: An Exciting Time
34
Industry Risk Reward Ratings
36
Table: Pharmaceuticals & Healthcare Risk/Reward Ratings, Q213
36
Rewards
37
Risks
38
Market Overview
40
Macroeconomic Forecasts
42
Economic Analysis
42
Dubai: Confident As Ever
42
Oman: An Exciting Time
45
Industry Trends And Developments
47
Epidemiology
47
Table: UAE Healthcare Demand Split By Therapeutic Area
48
Healthcare Sector
52
Healthcare Sector Developments
53
Health Insurance
58
Research & Development
63
Regulatory Development
65
Regulatory Regime
65
Regulatory Developments
66
Pharmacovigilance
67
Pharmaceutical Advertising
68
Intellectual Property Issues
68
Pricing Regime
70
Pricing And Reimbursement Developments
71
Regional Harmonisation
74
Competitive Landscape
77
Pharmaceutical Sector
77
Table: Abu Dhabi's Top Five Best Selling Drugs In Value Terms By Therapeutic Area
77
Domestic Industry
78
Foreign Industry
79
Recent Company Developments
80
Pharmaceutical Distribution And Retail
81
Recent Developments
82
Company Profile
84
Julphar
84
Modern Pharmaceutical Company
88
Neopharma
90
Medpharma
93
GlaxoSmithKline
95
Pfizer
97
Novartis
99
Johnson & Johnson
101
Sanofi Aventis
103
Abbott
105
Merck & Co
107
Demographic Forecast
109
Table: United Arab Emirates' Population By Age Group, 1990-2020 ('000)
110
Table: United Arab Emirates' Population By Age Group, 1990-2020
111
Table: United Arab Emirates' Key Population Ratios, 1990-2020
112
Table: United Arab Emirates' Rural And Urban Population, 1990-2020
112
Glossary
113
Methodology
115
Methodology
115
Risk/Reward Ratings Methodology
115
Ratings Overview
116
Table: Pharmaceutical Business Environment Indicators
116
Weighting
117
Table: Weighting Of Components
117
Sources
117

The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Emirati pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United Arab Emirates to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Emirati pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in United Arab Emirates.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc